A Phase 2 Open Label Extension Study of Conatumumab and AMG 479

Inclusion Criteria:

- To be enrolled in this study, subjects must be currently enrolled in a prior
Amgen-sponsored conatumumab or AMG 479 study and are eligible according to the parent
study to receive their next dose of conatumumab (with or without co-therapy), or AMG
479 alone.

Subjects must have their eligibility assessed for this study and be enrolled within 30
days of their last treatment on the parent protocol

Exclusion Criteria:

- Discontinued from a conatumumab study due to an adverse event considered by the
investigator to be related to conatumumab treatment, including intolerance to
conatumumab

- Subjects determined to have disease progression during their participation in the
parent Amgen study

- Woman or man with partner of childbearing potential not consenting to use adequate
contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm
plus condom), or abstinence during the course of the study and for 6 months after the
last dose of protocol-specified therapy administration

- Subject is pregnant or breast feeding, or planning to become pregnant within 6 months
after the last dose of protocol-specified therapy administration

- Male subject with a pregnant partner who is not willing to use a condom during
treatment and for an additional 6 months after the last dose of protocol-specified
therapy administration

- Subject has previously entered this study

- Subject will not be available for protocol required study visits, to the best of the
subject and investigator's knowledge

- Subject has any kind of disorder that, in the opinion of the investigator, may
compromise the ability of the subject to give written informed consent and/or to
comply with all required study procedures